D. Castèra

Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group

I. Ray-Coquard, E. Pujade-Lauraine, C. Martín, 2007, British Journal of Cancer.

Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients.

J. Misset, E. Cortesi, E. Gamelin, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.

B. Chauffert, J. Honnorat, D. Frappaz, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Étude desétats excites du 35Cl

P. Hubert, F. Leccia, D. Castèra, 1972 .

Sequential or simultaneous chemo-radiotherapy in operable breast cancer. A French multicentric phase III study — State of inclusions

L. Demange, C. Noguès, D. Serin, 1998 .

Prognostic value of health‐related quality of life for death risk stratification in patients with unresectable glioblastoma

B. Chauffert, F. Ducray, D. Frappaz, 2016, Cancer medicine.

Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.

E. Lemarié, B. Milleron, D. Spaeth, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.

L. Demange, E. Mouret‐Fourme, C. Noguès, 2006, International journal of radiation oncology, biology, physics.

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF.

B. Chauffert, J. Honnorat, D. Frappaz, 2014 .

Randomized multicenter phase II trial of irinotecan and bevacizumab as neoadjuvant and adjuvant to temozolomide-based chemoradiation versus chemoradiation for unresectable glioblastoma: Interim results of the TEMAVIR study from the ANOCEF group.

R. Guillevin, B. Chauffert, J. Honnorat, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.